The increasing prevalence of both obesity and depression is becoming a significant health
concern throughout the world. Evidence suggests a positive and bidirectional association between obesity
and depression. It is now well established that central serotonergic system is involved in the elicitation
of satiety signal and elevation of mood. Drugs that increase serotonin neurotransmission are
commonly recommended for the treatment of depression. But many patients are not benefitted by these
drugs, while remission rate is also not satisfactory. Serotonin based antiobesity drugs have been either
withdrawn from the market or disapproved for long term use. In view of critical need for novel therapeutic targets for obesity
and depression, the role of leptin is becoming increasingly important. The peptide hormone secreted by adipocytes
can cross blood brain barriers to elicit satiety signal via its receptors in the hypothalamus. Emerging evidence suggests
that the peptide hormone has a role in responses to stress and produces antidepressant like effects. On the other hand, both
obesity and depression are often associated with higher levels of leptin in circulation suggesting insensitivity to leptin. The
aim of the present article is to draw research interest towards exploring mechanism involved in leptin resistance. These
studies may facilitate the development of alternative treatment strategies, beyond serotonin based drugs, for obesity depression
and their comorbid condition.
Keywords: Obesity, depression, serotonin, leptin.
Rights & PermissionsPrintExport